# Daratumumab for Polyneuropathy Associated With MGUS

> **NCT06046287** · PHASE2 · WITHDRAWN · sponsor: **Georgetown University**

## Conditions studied

- Peripheral Neuropathy
- Monoclonal Gammopathy of Undetermined Significance

## Interventions

- **DRUG:** Daratumumab and hyaluronidase-fihj

## Key facts

- **NCT ID:** NCT06046287
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-09-26
- **Primary completion:** 2025-09-26
- **Final completion:** 2025-09-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06046287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06046287, "Daratumumab for Polyneuropathy Associated With MGUS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06046287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*